- $1.31bn
- $1.22bn
- $23.07m
Annual income statement for Enovix, fiscal year end - December 29th, USD millions except per share, conversion factor applied.
2020 December 31st | 2022 January 2nd | 2023 December 31st | 2023 January 1st | 2024 December 29th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 52 W | 52 W | 52 W | 52 W |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 7.64 | 6.2 | 23.1 |
| Cost of Revenue | |||||
| Gross Profit | — | — | -55.4 | -17 | -2.04 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 21.9 | 69.5 | 238 | 138 | 266 |
| Operating Profit | -21.9 | -69.5 | -230 | -132 | -243 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -39.6 | -126 | -215 | -51.6 | -224 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -39.6 | -126 | -214 | -51.6 | -223 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -39.6 | -126 | -214 | -51.6 | -222 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -39.6 | -126 | -214 | -51.6 | -222 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.284 | -1.07 | -1.32 | -0.305 | -1.11 |
| Dividends per Share |